Mindy Kitei, an investigative health journalist, science author, and former Philadelphia magazine and TV Guide editor who founded CFS Central to provide the comprehensive ME/CFS news and political coverage neglected by mainstream media, shared a post on X:
“FDA is holding up approval for Dr. Soon Shiong‘s Anktiva for papillary bladder cancer.
Take a minute to look at the cancer-free statistics from ChatGPT for Merck’s Keytruda, which was approved for papillary bladder cancer, vs Anktiva, which has yet to be approved for papillary bladder cancer, despite the fact that Anktiva is the superior drug for this disease.
At 24 months:
- Keytruda: ~30–40% disease-free.
- Anktiva+BCG ~52% disease-free.
At 3 years:
- 73% of Keytruda patients kept their bladders.
- 82% of Anktiva + BCG patients kept their bladders.
At 3 years:
- Keytruda overall survival: ~90%
- Anktiva + BCG overall survival: ~96%
Dr. Makary, Dr. Bhattacharya, and Sec Kennedy, please do the right thing and approve Anktiva for papillary bladder cancer now. Save more lives.
Please help spread the word and retweet this post.”
Other articles about Bladder Cancer on OncoDaily.